Zhejiang Taimei Medical Technology Co., Ltd. (TAIMEI TECH) disclosed a share repurchase on 22 July 2026, acquiring 307,400 H shares on the Hong Kong Stock Exchange at prices ranging between HKD 5.45 and HKD 5.77 per share. The volume-weighted average repurchase cost was approximately HKD 5.55, bringing total cash outlay to about HKD 1.71 million.

Following the transaction, TAIMEI TECH’s issued share capital (excluding treasury shares) fell by 0.16% to 197.18 million shares, while treasury share holdings increased to 3.42 million shares. The company’s total issued shares remained unchanged at 200.59 million.

The repurchase forms part of a mandate approved on 23 June 2026 that authorises the company to buy back up to 20.02 million shares—equivalent to 1.5% of the shares outstanding on the mandate date. Cumulative repurchases under this authority now stand at 2.996 million shares.

In accordance with Hong Kong listing rules, TAIMEI TECH is subject to a 30-day moratorium on issuing new shares or selling treasury shares, effective until 21 August 2026.